Psych CASC / OSCE · Psychopharmacology — pharmacogenomics
Explaining a commercial PGx report and HLA safety before carbamazepine (CASC)
CASC-style communication station: translate commercial PGx limits, explain HLA-B*15:02 testing before carbamazepine, shared decision, and no false guarantees.
On this page
Study tools
Target exams
Station instructions (candidate)
You have 7 minutes. Acknowledge fear of severe rash. Explain in plain language that some genetic tests (HLA) help estimate rare but serious carbamazepine skin-reaction risk and can guide whether to avoid that drug, while commercial multi-gene colour charts are only partly evidence-based and do not replace clinical judgement. Offer HLA-informed plan before carbamazepine, alternatives if high-risk allele present, and how CYP results (if present) may refine antidepressant dosing without guaranteeing outcome. Do not promise zero risk. Do not dismiss her report as useless without explaining what parts matter.[1][2][3]
References5ShowHide
- [1]Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update Clin Pharmacol Ther, 2018.PMID 29392710
- [2]Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan N Engl J Med, 2011.PMID 21428768
- [3]Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants Clin Pharmacol Ther, 2023.PMID 37032427
- [4]Bousman CA, Bengesser SA, Aitchison KJ, et al. Review and Consensus on Pharmacogenomic Testing in Psychiatry Pharmacopsychiatry, 2021.PMID 33147643
- [5]Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial JAMA, 2022.PMID 35819423